Evidence map›Paper›PMID 42171772›Full record

ArticleWorld journal of urology2026

Renal function outcomes following endoscopic management of upper tract urothelial carcinoma.

Philipp Korn, Mark Essien, Maximilian Pallauf, Joseph Cheaib, Soum Lokeshwar, Jaime O Herrera-Caceres, Alexander Small, Dima Raskolnikov, Nir Kleinmann, Asaf Shvero and 16 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Philipp KornDepartment of Urology, The Brady Urological Institute at Johns Hopkins, Johns Hopkins School of Medicine, 600 N. Wolfe Street/Park 213, Baltimore, MD, 21287, USA.
Mark EssienDepartment of Urology, The Brady Urological Institute at Johns Hopkins, Johns Hopkins School of Medicine, 600 N. Wolfe Street/Park 213, Baltimore, MD, 21287, USA.
Maximilian PallaufDepartment of Urology, The Brady Urological Institute at Johns Hopkins, Johns Hopkins School of Medicine, 600 N. Wolfe Street/Park 213, Baltimore, MD, 21287, USA.
Joseph CheaibDepartment of Urology, The Brady Urological Institute at Johns Hopkins, Johns Hopkins School of Medicine, 600 N. Wolfe Street/Park 213, Baltimore, MD, 21287, USA.
Soum LokeshwarDepartment of Urology, The Brady Urological Institute at Johns Hopkins, Johns Hopkins School of Medicine, 600 N. Wolfe Street/Park 213, Baltimore, MD, 21287, USA.
Jaime O Herrera-CaceresDepartment of Urology, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA.
Alexander SmallMontefiore Department of Urology, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY, USA.
Dima RaskolnikovMontefiore Department of Urology, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY, USA.
Nir KleinmannDepartment of Urology, Sheba Medical Center, Ramat Gan, Israel.
Asaf ShveroDepartment of Urology, Sheba Medical Center, Ramat Gan, Israel.
Surena F MatinDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Craig LabbateDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hristos KaimakliotisDepartment of Urology, Indiana University Medical Center, Indianapolis, IN, USA.
Isamu TachibanaDepartment of Urology, Indiana University Medical Center, Indianapolis, IN, USA.
Jennifer LinehanDepartment of Urology, Providence Specialty Medical Group, Santa Monica, CA, USA.
Jane ChoeDepartment of Urology, Providence Specialty Medical Group, Santa Monica, CA, USA.
Ojas ShahDepartment of Urology, Columbia University College of Physicians and Surgeons, New York, NY, USA.
Miyad MovassaghiDepartment of Urology, Columbia University College of Physicians and Surgeons, New York, NY, USA.
William HuangDepartment of Urology, New York University Grossman School of Medicine, New York, NY, USA.
Jesse PersilyDepartment of Urology, New York University Grossman School of Medicine, New York, NY, USA.
Aaron PerecmanDepartment of Urology, Lahey Hospital and Medical Center, Burlington, MA, USA.
David CanesDepartment of Urology, Lahey Hospital and Medical Center, Burlington, MA, USA.
Rodrigo R PessoaDepartment of Urology, Moffitt Cancer Center, Tampa, FL, USA.
Aaron PotretzkeDepartment of Urology, Mayo Clinic, Rochester, MN, USA.
Jay D RamanDepartment of Urology, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA.
Nirmish SinglaDepartment of Urology, The Brady Urological Institute at Johns Hopkins, Johns Hopkins School of Medicine, 600 N. Wolfe Street/Park 213, Baltimore, MD, 21287, USA. nsingla2@jhmi.edu.

Funding

Deutsche Forschungsgemeinschaft 571588707Paracelsus Medizinische Privatuniversität 2022-FIRE-004-Pallauf
6 · The paper itself

Abstract

purposeEndoscopic management offers renal-sparing approaches for upper tract urothelial carcinoma (UTUC). We sought to characterize the impact of endoscopically managing UTUC on kidney function and identify predictors of renal function decline.

methodsWe queried a multi-institutional cohort of endoscopically managed UTUC. Estimated glomerular filtration rate values 12 months after endoscopic treatment were assigned according to the National Kidney Function Kidney Disease Outcomes Quality Initiative (KDOQI) chronic kidney disease (CKD) stages. Loss of kidney function was defined as an increase by at least one CKD stage. Severe loss was defined as an increase by at least 2 CKD stages or development of CKD stage 3b-5.

resultsA total of 339 patients (521 interventions) were included. 113 patients (33.3%) experienced loss of kidney function and 75 (22.1%) experienced severe loss of kidney function. In multivariable logistic regression, high grade tumor (OR 2.29, 95% CI 1.23-4.33) and renal pelvic location (OR: 2.64, 95% CI 1.32-5.54) were significantly associated with loss of kidney function on a per-patient level. We observed similar results on a per-intervention analysis, with higher odds for kidney function loss for high grade tumor (OR 2.03, 95% CI 1.23-3.35) and renal pelvic location (OR 1.76, 95% CI 1.01-3.08).

conclusionDespite preservation of the renal unit, one-third of patients undergoing endoscopic management of UTUC experience loss of kidney function. High-grade tumors and renal pelvic location were associated with adverse renal function outcomes.

Indexed as

Carcinoma, Transitional CellGlomerular Filtration RateKidney NeoplasmsPostoperative ComplicationsRenal Insufficiency, ChronicUreteral NeoplasmsUreteroscopyAgedFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeChronic kidney diseaseEndoscopic managementRenal failureRenal functionUpper Tract Urothelial Carcinoma

Identifiers

PMID42171772

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.